黑龙江时时彩开奖时段
簡體|繁體
Announcement
Year:
2019
30/07/2019Notice of board meeting
19/07/2019Inside information (i) proposed subscription of shares of, (ii) exercise of conversion rights of convertible bond issued by, (iii) acquisition of sale loan notes issued by, Antikor Biopharma Limited and (iv) IP licence agreement
19/07/2019Inside information further updates on U.S. FDA first phase 3 clinical trial relating to dry eye disease
11/07/2019Inside information further updates in relation to co-development agreement U.S. FDA first phase 3 clinical trial relating to dry eye disease
30/04/2019Poll results of the annual general meeting held on 30 April 2019
18/03/2019Notice of annual general meeting
11/03/2019Annual results announcement for the year ended 31 December 2018
26/02/2019Notice of board meeting
14/01/2019Terms of Reference - Audit Committee
2018
30/10/2018Inside Information proposed subscription of Convertible Notes and License Agreement
29/10/2018Inside Information updates in relation to Co-Development Agreement U.S. FDA first Phase 3 Clinical Trial related to dry eye disease
22/08/2018Inside Information approval to commercialise preservative-free single-dose Sodium Hyaluronate Eye Drops in China
08/08/2018Interim results for the six months ended 30 June 2018
26/07/2018Notice of board meeting
18/07/2018Inside Information proposed investment in Chengdu Shanggong Medical Technology Co., Ltd.
18/07/2018Discloseable Transaction acquisition of land use rights and construction of production plant in Zhuhai, PRC
17/07/2018Inside information approval to commercialise preservative-free single-dose Levofloxacin Eye Drops in China
16/07/2018Discloseable Transaction in relation to Co-Development Agreement
29/06/2018Inside Information investment agreements entered into with Zhuhai National High-Tech Industrial Development Zone Management Committee
27/06/2018Grant of Share Options
11/05/2018Poll results of the annual general meeting held on 11 May 2018
11/04/2018Announcement update on the commercialisation of the preservative-free single-dose tobramycin eye drops in china
27/03/2018Notice of annual general meeting
15/03/2018Annual results announcement for the year ended 31 December 2017
02/03/2018Notice of board meeting
28/02/2018Change of Company Logo
25/02/2018 Inside Information proposed subscription of convertible preferred C shares of MeiraGTx Limited
2017
13/12/2017Supplemental announcement in relation to contract for investor and media relations services and grant of share option
29/11/2017Discloseable Transaction Second Supplemental Agreement To Existing Agency Agreement
01/11/2017Announcement contract for investor and media relations services and grant of share options
17/10/2017Supplemental announcement in relation to the annual report for the year ended 31 December 2016 and the interim report for the six months ended 30 June 2017
16/10/2017Inside Information Termination of the proposed establishment of Korean Depositary Receipt Programme on the Korea Exchange
11/08/2017Interim results for the six months ended 30 June 2017
24/07/2017Notice of board meeting
13/06/2017Announcement approval to commercialise preservative-free single-dose Tobramycin Eye Drops in China
23/05/2017Change of name and address of share registrar and transfer agent in the Cayman Islands
22/05/2017Inside Information Research Project Agreement with AC IMMUNE SA
16/05/2017Inside Information Commencement of prior consultation with the Korea Exchange in respect of the proposed Korean Depositary Receipt Programme
27/04/2017Poll results of the annual general meeting held on 27 April 2017
24/03/2017Notice of annual general meeting
21/03/2017Annual results announcement for the year ended 31 December 2016
08/03/2017Inside Information Possible Establishment of Korean Depositary Receipt Programme on the Korea Exchange
07/03/2017Notice of board meeting
07/03/2017Voluntary Announcement 2017 National Insurance Drug List
2016
11/11/2016Grant of share options
26/09/2016Voluntary Announcement-Update on investment in AC IMMUNE SA
05/08/2016Interim results for the six months ended 30 June 2016
25/07/2016Notice of board meeting
06/07/2016Convertible loan from International Finance Corporation
09/05/2016Poll results of the annual general meeting held on 9 May 2016
12/04/2016Subscription of series E preferred shares in AC IMMUNE SA
24/03/2016Notice of annual general meeting
18/03/2016Annual results announcement for the year ended 31 December 2015
08/03/2016Notice of board meeting
03/03/2016Inside information distribution agreement with Elektron Technology UK Limited
25/01/2016Inside information-Collaboration and license agreement and proposed subscription of series C preferred stock and warrants
08/01/2016Inside information - Convertible loan agreement
2015
31/12/2015Terms of Reference - Audit Committee
22/12/2015Inside information - Agency agreement
30/11/2015Inside information-Convertible loan agreement
22/09/2015Announcement agency agreement with Guangxi Medictop Pharmaceutical Co.,Ltd.
28/08/2015Announcement strategic co-operation framework agreement
10/08/2015Interim results for the six months ended 30 June 2015
29/07/2015Notice of board meeting
17/07/2015Announcement change in board lot size
28/05/2015Announcement distribution agreement with Elektron Technology UK Limited
14/05/2015Announcement included by MSCI as a constituent of the MSCI Global Small Cap Indexes-China
08/05/2015Poll results of the annual general meeting held on 8 May 2015
28/04/2015Announcement agency agreement with Wuhan Adv.dental Co.,Ltd
23/03/2015Notice of annual general meeting
18/03/2015Annual results announcement for the year ended 31 December 2014
06/03/2015Notice of board meeting
2014
19/08/2014Announcement strategic co-operation framework agreement with Wenzhou Medical University
07/08/2014Interim results for the six months ended 30 June 2014
28/07/2014Notice of board meeting
15/05/2014Announcement obtaining of a health food certificate by a wholly-owned subsidiary
05/05/2014Poll results of the annual general meeting held on 5 May 2014
18/03/2014Notice of annual general meeting
07/03/2014Annual results announcement for the year ended 31 December 2013
25/02/2014Notice of board meeting
17/02/2014Announcement import and service agreement with Pfizer international trading (ShangHai) LTD.
2013
31/12/2013Announcement obtaining of a certificate of good manufacturing practices for human drugs by a wholly-owed subsidiary
30/10/2013Announcement contract for investor relations services and grant of share options under the share option scheme
14/08/2013Interim results for the six months ended 30 June 2013
01/08/2013Notice of Board Meeting
08/05/2013Announcement increase in total investment and registered capital of a wholly-owned subsidiary
03/05/2013Poll results of the annual general meeting held on 3 May 2013
27/03/2013Notice of annual general meeting
22/03/2013Annual results announcement for the year ended 31 December 2012
12/03/2013Notice of Board Meeting
24/01/2013Change of principal share registrar and transfer agent in the Cayman Islands
2012
07/08/2012Interim results for the six months ended 30 JUNE 2012
26/07/2012Notice of Board Meeting
07/05/2012Poll Results at the Annual General Meeting Held on 7 May 2012
29/03/2012Terms of Reference-Remuneration Committee
29/03/2012Terms of Reference-Nomination Committee
29/03/2012Terms of Reference-Audit Committee
29/03/2012List of Directors and their Role and Function
29/03/2012Notice of annual general meeting
23/03/2012Announcement of annual results for the year ended 31 December 2011
美国nba投注量 重庆时时彩稳赚公式 赛车双人游戏大全 抢庄牌九下载v2.0 网络棋牌炸金花规律 重庆时时全天候计划 2018女篮亚洲杯决赛 网上通比牛牛有假吗 北京pk10稳赚心得技巧 苹果彩票下载 重庆时时开奖官方同步 排三6码遗漏组六分析 重庆时时彩计划软件 幸运飞艇稳赚经验分享 阿尔杰罗本 上海时时哪里有卖